1932

Abstract

The development of new anticoagulants is expanding the list of drugs that can be used to prevent and treat venous and arterial thrombosis. New parenteral anticoagulants have been developed to overcome the limitations of heparin and low-molecular-weight heparin, whereas novel orally active anticoagulants have been designed to provide more streamlined therapy than vitamin K antagonists. This review identifies the molecular targets of new anticoagulants, describes the results of clinical trials, and provides clinical perspective on the opportunities for new anticoagulants.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.med.56.082103.104708
2005-02-18
2024-04-29
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.med.56.082103.104708
Loading
/content/journals/10.1146/annurev.med.56.082103.104708
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error